Dr. Amita Gupta, MD, MHS - Baltimore, MD - Infectious Diseases

Professional Titles

Director, Division of Infectious Diseases, Johns Hopkins School of Medicine
Founder & Faculty Co-chair, Johns Hopkins India Institute

Primary Academic Title

Professor of Medicine

Johns Hopkins Physician

Background

Dr. Gupta is the Florence Sabin Professor of Infectious Diseases and Director of the Division of Infectious Diseases at the Johns Hopkins School of Medicine, and she holds a joint appointment in the Department of International Health at the JH Bloomberg School of Public Health. She is a practicing physician at Johns Hopkins Hospital.

Dr. Gupta’s work focuses on international clinical research, public health, and education in infectious diseases, with specialties in HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her research has focused primarily on India, where she leads several JHU research collaborations. She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. She is a faculty member of the Center for Infectious Diseases in India, and is the founder and Faculty Steering Committee Co-chair of the Gupta-Klinsky India Institute (GKII). GKII brings together more than 165 faculty from across 7 Johns Hopkins University schools to collaborate with Indian institutions on research, programs, and policies that serve Indo-US national and global interests.

She is an active clinical investigator in multi-country trials conducted by the Advancing Clinical Therapeutics Globally (ACTG) network and the International Maternal Pediatric Adolescent AIDS Trials network (IMPAACT), and she has served as protocol chair for high impact TB prevention studies that have resulted in publications in The New England Journal of Medicine and The Lancet.

During the COVID pandemic, she was a member of The Johns Hopkins Precision Medicine Center of Excellence for COVID-19, cared for patients with COVID, and helped to galvanize community resources for COVID response in the US and in India.

Dr. Gupta’s other scientific leadership positions include serving as Vice-Chair for the IMPAACT TB Scientific Committee. She is US Chair for the Indo-US Vaccine Action Program-sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology since 2013. She also is a member of the global RePORT International Executive Committee, a multilateral global consortia for TB research, and Co-principal Investigator of the NIH-funded Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI-CTU). She previously served on the Johns Hopkins Precision Medicine Center for Excellence for COVID-19, and in 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum, and in 2023 was appointed to serve on the Association of American Universities’ Task Force on Expanding United States-India Partnerships. She is a Founder’s Circle member of Indiaspora.

Dr. Gupta is an author of more than 250 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has mentored more than 40 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.

Dr. Gupta received an undergraduate degree from Massachusetts Institute of Technology (MIT) in Materials Science Engineering, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from Johns Hopkins Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the Johns Hopkins School of Medicine (Infectious Diseases).

Centers and Institutes

LinkedIn

https://www.linkedin.com/in/amita-gupta-91720316/

Clinical Trial Keywords

Tuberculosis; HIV; PMTCT; Breastfeeding; Antiretroviral; MDR-TB; Maternal and Infant Health; TB preventive therapy; drug-resistant infections

Clinical Trials Summary

ACTG 5300/IMPAACT 2003: Phase III, Open Label, Multi-center Trial: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
HATHI: Hybrid Trial for Alcohol Reduction among People with TB and HIV in India
Regional Prospective Observational Research for Tuberculosis (RePORT) International
Regional Prospective Observational Research for Tuberculosis (RePORT) India
IMPAACT 1078: Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
Hinduja-Hopkins TB Research Observational Clinical Database
Impact of Diabetes on TB Treatment Outcomes:
Dynamics and Immune Mechanisms of QFT Response in Close Contacts of TB Cases
A Nanopore Biosensor for Leveling MTB Antigens in Blood
Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis
Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)
Inflammasome Genetics and Tuberculosis Treatment Outcomes
ACTG 5274: Phase IV, Open Label Strategy Trial: REMEMBER: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens
Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but Resistant to MTB Infection
Host RNA Expression for Diagnosis and Monitoring of Pediatric TB in Africa and India
Molecular Signatures of Tuberculosis-Diabetes Interaction
Validation of Transcriptional Signature to Predict Active TB Disease among Advanced HIV Patients
Residual Respiratory Impairment Following Pulmonary Tuberculosis
Implementing the Comprehensive Unit-based Safety Program to Reduce Healthcare-Associated Sepsis in the Neonatal Intensive Care Unit in Pune, India
Evaluating the Source of Neonatal Bloodstream Infections due to Classically Hospital Acquired Pathogens in the Neonatal Intensive Care Unit in Pune, India
Gut Microbiota of HIV Infected Pregnant Women
TREAT Asia Observational Database
COVID analyses: JH CROWN Registry

Find a Clinical Trial

View all trials by this principal investigator.

Videos

Recent News Articles and Media Coverage

NIH grant cuts will axe clinical trials abroad — and could leave thousands without care Nature May 30, 2025
Hopkins India Conference debuts: In conversation with Dr. Amita Gupta Thje American Bazaar, May 1, 2025
Fighting active and latent TB in schools: A keystone in India's TB elimination strategy?, ETHealthworld Jan 6, 2025
With high unhealthy alcohol use and increased risk of TB, counseling holds a solution Scroll June 21, 2023
Johns Hopkins Medicine awarded $10 million to optimize antibiotic therapy for bacterial infections | EurekAlert! November 21, 2022
The NIH/DAIDS Cross-Network (ACTG/HVTN/IMPAACT) TB Vaccine Working Group calls for people living with HIV to be included in tuberculosis vaccine development | EurekAlert! October 11, 2022
Johns Hopkins Medicine-led consortium to receive up to $200 million to fight TB globally The HUB August 17, 2022
India is a critical partner in addressing global public health challenges Economic Times June 8, 2022
Amita Gupta Named Director of Johns Hopkins Medicine's Division of Infectious Diseases, Newswise Feb 3, 2022
Johns Hopkins Students and Faculty Members Confront India's COVID-19 Crisis. Johns Hopkins Medicine. July 8, 2021
7 Lessons We've Learned from this Pandemic to Remember for the Next One. SELF. June 22, 2021
India COVID-19 Outbreak Could 'Spread Around the World,' Expert Warns. International Business Times. May 13, 2021
Indian Students in US Anxious about COVID-19 Back Home. VOA News. May 13, 2021
Johns Hopkins University Helping India Fight Covid Surge. CBS Baltimore. May 13, 2021
Johns Hopkins expert Dr. Amita Gupta on India's covid 19 challenge & future preparedness options. Financial Express. May 12, 2021
India's COVID-19 Disaster May Be Turning Into an Even Bigger Global Crisis. TIME. May 12, 2021
How the US can help the COVID crisis in India. The Hill. May 4, 2021
India's crushing COVID caseload the result of 'perfect storm' of factors, experts say. USA Today. April 28, 2021
As COVID Crisis Unfolds in India, Johns Hopkins Rushes to Help. Johns Hopkins Hub. April 28, 2021
A Bold New Chapter Begins for Hopkins and India. Johns Hopkins Hub. April 26, 2021
Trump Briefly Leaves Hospital for Photo Op With Supporters. New York Magazine. October 4, 2020
Johns Hopkins Researchers Publish COVID-19 'Prediction Model.' Johns Hopkins Medicine. September 23, 2020
Study Shows Extent, Danger of TB Exposure, Part 1. Medical Daily. August 24, 2020
International Johns Hopkins Study Says Broad Measures needed to Prevent TB Spread in India. Johns Hopkins Research Story Tip. August 6, 2020
In Women with HIV, TB Preventive Therapy Poses Greater Risk in Pregnancy than Postpartum. NIH Press Release. October 2, 2019

Contact for Research Inquiries

1830 East Monument Street, Room 437
Baltimore, MD 21287

Phone: (410) 502-7696

Research Interests

TB, antimicrobial resistance, HIV, diarrheal diseases epidemiology, global health, infectious diseases, emerging infections, COVID-19, clinical trials, studies in adults, including pregnant women, and children

Lab Website

Amita Gupta Lab - Lab Website

The Amita Gupta Lab focuses on drug trials to prevent and treat HIV, tuberculosis (TB) and other infectious diseases and comorbidities in adults, including pregnant women, and children who reside in low-and middle-income settings. We also conduct cohort and translational science studies assessing TB, HIV, and antimicrobial resistance in international settings.

Google Scholar - Publications

https://scholar.google.com/citations?user=WuXtPTgAAAAJ&hl=en&oi=ao

PubMed - Publications

https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Amita+Gupta&sort_order=desc

Selected Publications

Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona A, Gonzales P, Comins K, Shenje J, Nerette Fontain S, Omozoarhe A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C, Harrington M, Shah NS, Hesseling AC, Churchyard G, Swindells S, Gupta A; AIDS Clinical Trials Group (ACTG) A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) I2003 Protecting Households on Exposure to Newly Diagnosed Index Multidrug-resistant Tuberculosis Patients (PHOENIx) Feasibility Study Team. One-year incidence of tuberculosis infection and disease among household contacts of rifampin- and multi-drug resistant tuberculosis. Clin Infect Dis. 2023 May 25:ciad301. doi: 10.1093/cid/ciad301. Epub ahead of print. PMID: 37227925.
Miner MD, Hatherill M, Mave V, Gray GE, Nachman S, Read SW, White RG, Hesseling A, Cobelens F, Patel S, Frick M, Bailey T, Seder R, Flynn J, Rengarajan J, Kaushal D, Hanekom W, Schmidt AC, Scriba TJ, Nemes E, Andersen-Nissen E, Landay A, Dorman SE, Aldrovandi G, Cranmer LM, Day CL, Garcia-Basteiro AL, Fiore-Gartland A, Mogg R, Kublin JG, Gupta A, Churchyard G. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022 Nov;9(11):e791-e800. doi: 10.1016/S2352-3018(22)00255-7. Epub 2022 Oct 11. Erratum in: Lancet HIV. 2022 Dec;9(12):e822. PMID: 36240834; PMCID: PMC9667733.
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.
Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Chandrasekaran PD, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study. Eur Respir J. 2021 Oct 28:2100905. doi: 10.1183/13993003.00905-2021. Epub ahead of print. PMID: 34711538.
Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, Schumock G, Nagy P, Gray JH, Malapati H, Ghobadi-Krueger M, Niessen TM, Kim BS, Hill PM, Ahmed MS, Dobkin ED, Blanding R, Abele J, Woods B, Harkness K, Thiemann DR, Bowring MG, Shah AB, Wang MC, Bandeen-Roche K, Rosen A, Zeger SL, Gupta A. Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. Ann Intern Med. 2021 Jan;174(1):33-41. doi: 10.7326/M20-3905. Epub 2020 Sep 22. Erratum in: Ann Intern Med. 2021 Jan;174(1):144. PMID: 32960645; PMCID: PMC7530643
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia JV, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE for the BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001-1011. DOI: 10.1056/NEJMoa1806808.
Mave V, Chandanwale A, Kagal A, Khadse S, Kadam D, Bharadwaj R, Dohe V, Robinson ML, Kinikar A, Joshi S, Raichur P, McIntire K, Kanade S, Sachs J, Valvi C, Balasubramanian U, Kulkarni V, Milstone AM, Marbaniang I, Zenilman J, Gupta A. High Burden of Antimicrobial Resistance and Mortality Among Adults and Children With Community-Onset Bacterial Infections in India. J Infect Dis. 2017 Apr 15;215(8):1312-1320. doi: 10.1093/infdis/jix114. PMID: 28329303; PMCID: PMC5853545.

Honors

2018 Johns Hopkins School of Medicine 125th Anniversary "Living the Hopkins Mission" Honoree

Graduate Program Affiliations

Memberships

Infectious Diseases Society of America
American Medical Association
American Society of Tropical Medicine and Hygiene
The International Union Against Tuberculosis and Lung Disease (The Union)

Professional Activities

Johns Hopkins Gupta-Klinsky India Institute, Founder and Faculty Co-chair
PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial, Co-Chair
NIH/Indian Government TB Research Consortium (RePORT India), Co-Chair
ACTG TB transformative Science Group, Member
Executive Committee, RePORT International, Member
IMPAACT TB Scientific Committee, Vice Chair
Indo-US Science and Technology Forum (IUSTTF), Governing Board Member
JH COVID-19 CROWN registry research, Faculty
NIAID Advisory Council, Member, 2019-2023
ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection, Vice Chair
IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings, Chair
Union Interest Group in Maternal-Infant TB working group, Member

Amita Gupta, MD, MHS

Highlights

Age Groups Seen

Languages

In-Network Plans

Gender

Johns Hopkins Affiliations:

About Amita Gupta